Other Information
−Removed: We have used, and intend to continue to use, our Investor Relations website and social media sites, which may include Facebook, Instagram, LinkedIn, StockTwits, Twitter, Yahoo, and YouTube pages, as means of disclosing material non-public information and
−Removed: for complying with our disclosure obligations under Regulation FD.
−Removed: Therefore, we encourage investors, the media, and others interested in our company to review the information we post on such social media channels.
EXHIBIT INDEX
13 unchanged sentences
Amended and Restated Bylaws of Plus Therapeutics, Inc.
+Added: Description of Securities .
Form of Common Stock Certificate .
−Removed: Form of Series T Warrant .
−Removed: Form of Series T Warrant Agreement between Plus Therapeutics, Inc.
−Removed: and Broadridge Corporation Issuer Solutions, Inc .
Form of Series U Warrant .
1 unchanged sentence
Form of Underwriters’ Warrant Amendment Agreement
−Removed: Purchase Agreement, dated September 30, 2020, by and between Plus Therapeutics, Inc.
−Removed: and Lincoln Park Capital Fund, LLC
−Removed: Registration Rights Agreement, dated September 30, 2020, by and between Plus Therapeutics, Inc.
−Removed: and Lincoln Park Capital Fund, LLC
+Added: Master Services Agreement between Piramal Pharma Solutions, Inc.
+Added: and Plus Therapeutics, Inc.
+Added: Exhibit 10.24
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section
−Removed: 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certifications Pursuant to 18 U.S.C.
8 unchanged sentences
34‑47986, the certifications furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10‑Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates it by reference.
+Added: Portions of the exhibit (indicated by asterisks) have been omitted.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
PLUS THERAPEUTICS, INC.
−Removed: October 22, 2020
+Added: April 22, 2021
President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)
/s/ Andrew Sims
−Removed: October 22, 2020
+Added: April 22, 2021
Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.